The Official Journal of EuroPCR and the European Association of Percutaneous Coronary Interventions (EAPCI)

Editorial

Valvular heart disease: the unanswered questions

EuroIntervention 2015;11:W11-W13. DOI: 10.4244/EIJV11SWA2

1. Department of Cardiology, St Thomas’ Hospital, London, United Kingdom; 2. Department of Cardiology, Clinique Pasteur, Toulouse, France; 3. Cardio-Thorax-Vascular and Transplant Department, University of Catania, Catania, Italy; 4. Medical Clinic I, Stä
Valvular heart disease (VHD) is common yet poorly researched and an important cause of heart failure, arrhythmia, recurrent hospital admission, reduced quality of life and early mortality. Due to the ageing of the population in developed nations, a new epidemic of degenerative VHD is upon us, heralding a major increase in the healthcare resources required for its optimal management1.

The evidence base to guide the optimal management of VHD was remarkably weak in comparison with other areas of cardiovascular disease until the recent advent of transcatheter valve therapies. There have been virtually no randomised controlled trials (RCTs) and international ...

Sign in to read and download the full article

Forgot your password?
No account yet? Sign up for free!
Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Read next article
Multiple valve disease - assessment, strategy and intervention